UAE at a glance
- Population
- 11.5 million 2025
- Life expectancy at birth
- 83.1 years, 2024
- People aged 65 and over
- 1.8 % of people, 2025
- Health spending per person
- 2,402 US$ per person, 2023
- Doctors
- 2.99 per 1,000 people, 2023
Updated
Reviewed by Chandani Patel
UAE Anti-Snoring Devices Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Device Type, By End User, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034F
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$10.0 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $6.9 Mn | — | — |
| 2025 (base) | $7.6 Mn | +$0.7 Mn | — |
| 2026 (forecast) | $8.3 Mn | +$0.7 Mn | +9.8% |
| 2027 (forecast) | $9.2 Mn | +$0.8 Mn | +20.6% |
| 2028 (forecast) | $10.1 Mn | +$0.9 Mn | +32.4% |
| 2029 (forecast) | $11.0 Mn | +$1.0 Mn | +45.3% |
| 2030 (forecast) | $12.1 Mn | +$1.1 Mn | +59.6% |
| 2031 (forecast) | $13.3 Mn | +$1.2 Mn | +75.2% |
| 2032 (forecast) | $14.6 Mn | +$1.3 Mn | +92.4% |
| 2033 (forecast) | $16.0 Mn | +$1.4 Mn | +111.3% |
| 2034 (forecast) | $17.6 Mn | +$1.6 Mn | +132% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $7.6 Mn placeholder estimate |
|---|---|
| Forecast, 2034 | $17.6 Mn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.8% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Device type and end user (see all) |
| Key players | ResMed Inc., Koninklijke Philips N.V., SomnoMed, Fisher & Paykel, Apnea Sciences and 1 more (see all) |
| Regulator in the UAE | EDESource: Emirates Drug Establishment. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Approximately 25% to 50% of adults snore regularly, with about 90 Mn Americans reporting snoring at some point in their lives, and 37 Mn stating they snore regularly. It stems from the inflammation of tissues in the upper airway and causes life-threatening risks such as cardiovascular disease and diabetes. Positional devices, oral appliances, positional aids, and continuous positive airway pressure (CPAP) treatments provide relief by enhancing airflow and avoiding blockage of airways during sleeping.
The market for the anti-snoring device has been growing because of growing awareness of sleep disorders, increasing obesity rates, and the growing elderly population. There is a growing popularity in both invasive and non-invasive treatment options, which include nasal devices, mandibular advancement devices, CPAP machines, and smart wearables. North America is the largest market for injectable drugs followed by Europe and Asia-Pacific, primarily due to increasing accessibility and understanding of healthcare requirements in emerging nations like China and India. Market growth is supported by technology development and new product development.
The market of anti-snoring devices is advancing because of increase in the incidence of snoring problems like obstructive sleep apnea due to obesity and increased life span. Awareness of the relative risks to health and greater comfort and convenience offered by technological advancements in devices are other factors that are driving the demand. On the same note, a rising elderly and overweight population, coupled with rising healthcare expenditure and promotional campaigns on health, is leading to the continued growth of the market.
The markets with future development opportunities in the anti-snoring devices market are the Asia-Pacific and Latin American markets, which are experiencing enhancements in healthcare systems and a rise in awareness of this condition. Smart features like smart sensors, wireless solutions, and tailored functions will improve device desirability and performance.
Some of the challenges affecting the anti-snoring devices market are discomfort among the users, high prices especially where the devices have to be custom made, and questions of inefficiency and lack of adequate scientific evidence. Lack of acceptance related to snoring and competition from related products such as CPAP machines and surgeries also pose as constraints to market growth. Moreover, in areas that are not very exposed to health promotion and awareness campaigns, gaps in knowledge deter demand.
December 2025, For the first time, the FDA cleared oral devices that treat severe obstructive sleep apnea (OSA). These devices offer an alternative to more common sleep apnea treatments, like continuous positive airway pressure (CPAP) therapy and surgery.
November 2022, Prosomnus announced Nov. 2, 2022, that it received FDA 510(k) clearance for its ProSomnus EVO [PH] sleep and snore device, a precision oral appliance therapy (OAT) device.
February 2021, The FDA authorized marketing of a new prescription device, eXciteOSA, to reduce snoring and mild obstructive sleep apnea. It is the first device used while awake that is intended to improve tongue muscle function, which in time can help prevent the tongue from collapsing backwards and obstructing the airway during sleep.
July 2024, EnsoData announces the acquisition of sleep testing diagnostic technology from Resonea aimed at reducing the cost of systematically addressing sleep apnea across large patient populations. With this acquisition, EnsoData adds acoustic flow and microphone data channels to enable an exciting new way to pre-screen patients for sleep apnea with an FDA-cleared mobile application and extend the diagnostic capabilities of home sleep testing.
The Emirates Drug Establishment (EDE), set up in 2023, is taking over the regulation of medical devices from the Ministry of Health and Prevention.[1] Since January 2025, basic health insurance has been mandatory for all private-sector employees and domestic workers in every emirate.[2]
[1] Emirates Drug Establishment. Checked 14 Nov 2026.
[2] Ministry of Human Resources and Emiratisation. Checked 14 Nov 2026.
Regulatory shifts and favourable healthcare campaigns are fostering the use of anti-snoring devices because sleep disorders, including snoring, and OSA are significant concerns. The deregulation of the approval systems and emphasis placed on minimally invasive procedures are positively influencing the development of new products and market participation. The role of reimbursement scenarios is prominent in the context to insurance coverage in regions involving North America that escalates the adoption. An emerging market is present as existing potential markets can progress over time, and this is also applicable to healthcare systems that can improve the access and reimbursement of anti-snoring treatments.
What doctors and scientists are doing in Anti-Snoring Devices right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 16 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
UAE · 1 shared keyword
UAE · 1 shared keyword
UAE · 1 shared keyword
UAE · 1 shared keyword
UAE · 1 shared keyword
UAE · 1 shared keyword
Pharmaceuticals · UAE
Pharmaceuticals · UAE
Pharmaceuticals · UAE
Digital Health · UAE
Public Health · UAE
Pharmaceuticals · UAE